Caption Management’s CorMedix CRMD Stock Holding History

Caption Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$86.9K	Buy	+12,800	New	+$94.6K	﹤0.01%	1404

Other funds holding CRMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Caption Management's CRMD Position: Q2 2025 in Review

Caption Management sold out of CorMedix (CRMD) in Q2 2025, closing a stake of 18,409 shares — an estimated $113K sold.

Caption Management first reported a position in CRMD in Q1 2025 and held it in 1 quarter. The position peaked at $113K in Q1 2025. 172 funds tracked by Wall St. Rank hold CRMD as of Q2 2025.

Caption Management reported no remaining CorMedix position as of Q2 2025 after selling out during the quarter.
Caption Management sold 18,409 CorMedix shares in Q2 2025, an estimated $113K.
Caption Management first reported a position in CorMedix in Q1 2025 and held it in 1 quarter.
Caption Management's CorMedix position peaked at $113K in Q1 2025.
172 funds tracked by Wall St. Rank held CorMedix as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.